Drug Database
ET

ethinyl estradiol + norethindrone (WC3026 / Generess Fe)

✓ Approved

Actavis · ESR1 · Small Molecule

What is ethinyl estradiol + norethindrone?

ethinyl estradiol + norethindrone is a small molecule developed by Actavis. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesWC3026, Generess Fe
CompanyActavis
Drug ClassSmall Molecule
Molecular TargetESR1, PGR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Actavis

Mechanism of Action

Molecular Targets

ethinyl estradiol + norethindrone acts on 2 molecular targets:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Related Research Articles

PubMedReproductive biology and endocrinology : RB&E2026-06-02

Pharmacodynamic interaction analysis of dydrogesterone, progesterone, and estradiol in combination-progestin HRT frozen embryo transfer: a prospective clinical cohort study.

Eggersmann Tanja K TK, Hamala Noemi N, Hiller Roman Alexander Friedrich RAF, Depenbusch Marion M et al.

In anovulatory hormone replacement therapy frozen embryo transfer (HRT-FET) cycles, reproductive success depends entirely on exogenous sex-steroid supplementation. Inadequate progesterone exposure remains a clinically relevant challenge, affecting up to one-third of patients receiving micronized vaginal progesterone (MVP) monotherapy. Combination regimens incorporating oral dydrogesterone (DYD) alongside MVP have been proposed to address this limitation. Critically, the absence of immunoassay cross-reactivity between DYD and progesterone enables simultaneous quantification of both progestins within a single patient - a methodological opportunity not yet exploited in outcome research. Using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS), we investigated the independent and joint associations of DYD, dihydrodydrogesterone (DHD), progesterone (P), and estradiol (E2) with clinical outcomes in a combination-progestin HRT-FET regimen, establishing a novel pharmacodynamic interaction framework for HRT-FET protocol optimization. This nested analysis included 111 women undergoing anovulatory HRT-FET within a prospective multicenter cohort (NCT03507673). Patients received oral estradiol (2 mg tid) followed by MVP (400 mg bid) and DYD (10 mg tid) from days 13-15. Serum and plasma samples collected on the day of FET were analyzed using HPLC-MS/MS for DYD and DHD, and immunoassay for P and E2. Clinical pregnancy and live birth were assessed as primary outcomes. Stratified and interaction analyses were performed to explore combined hormone-level effects. Hormone concentrations showed broad interindividual variability with weak inter-analyte correlations (r ≤ 0.33), confirming pharmacodynamic independence of the two progestin pathways. No statistically significant independent association with live birth was observed for any single analyte. However, interaction analyses revealed consistent gradient patterns: live birth rates were highest when both DYD and P concentrations were elevated (67%) and lowest when both were in the lower range (27%). Analogous patterns were observed for DYD-E2 and P-E2 combinations, suggesting additive and substitutive pharmacodynamic interaction effects. Given the hypothesis-generating nature of this study, the sample size is appropriate for the exploratory interaction framework established here. This study introduces simultaneous dual-progestin quantification as a methodological platform for pharmacodynamic interaction research in HRT-FET. Exploratory interaction patterns between both progestins and estradiol suggest clinically relevant additive effects, while patterns between the two progestins are compatible with potential substitutive dynamics that can only be evaluated within combination regimens without analytical cross-reactivity. These findings provide a mechanistic framework and generate hypotheses for adequately powered prospective studies investigating joint hormone exposure and reproductive outcomes. NCT03507673.

PMID 42226298
Read full article →
PubMedBMC women's health2026-06-02

Comparison of two menopausal hormone therapy regimens in managing menopausal symptoms: a retrospective study.

Yu Yanqin Y, Lv Mengqin M, Fu Yanhong Y

Femoston (estradiol/dydrogesterone) and Climen (estradiol valerate/cyproterone acetate) are two widely prescribed sequential menopausal hormone therapy (MHT) regimens that differ in estrogen formulation, progestogen component, and sequential pattern. Head-to-head comparative data on their clinical efficacy and safety remain scarce. This single-center retrospective study enrolled 80 perimenopausal and early postmenopausal women who received Femoston (n = 42) or Climen (n = 38) for six consecutive treatment cycles between January 2022 and January 2025. The primary outcome was post-treatment Kupperman Menopausal Index (KMI) score assessed by multivariable linear regression. Secondary outcomes included individual symptom response rates, serum sex hormone levels, lipid profile, hepatic enzymes, fasting plasma glucose, endometrial thickness, and adverse events. Both regimens produced substantial reductions in KMI scores from baseline (Femoston: 26.90 ± 5.72 to 10.48 ± 3.72; Climen: 27.53 ± 6.08 to 11.74 ± 4.12; both P < 0.001). After multivariable adjustment, treatment group was not independently associated with post-treatment KMI score (β = 0.58, 95% CI: -0.82 to 1.98, P = 0.412). Response rates for hot flashes/sweating, insomnia, and mood symptoms were comparably high between groups (all P > 0.05). Both regimens significantly suppressed FSH and LH and elevated E₂. Regarding lipid profiles, Femoston significantly increased HDL-C (P = 0.001) whereas Climen did not (P = 0.402); Climen significantly increased TG (P = 0.048) whereas Femoston did not (P = 0.583). After Benjamini-Hochberg correction, the between-group difference in HDL-C remained significant (adjusted P = 0.024). No clinically significant changes in hepatic enzymes, fasting glucose, or endometrial thickness were observed in either group, and no serious adverse events occurred. Femoston and Climen provide comparable short-term menopausal symptom relief. The more favorable lipid profile with Femoston, particularly its HDL-C benefit, may inform individualized regimen selection, especially in women without indications for antiandrogenic therapy. Prospective studies with longer follow-up are warranted to evaluate hard cardiovascular endpoints.

PMID 42226203
Read full article →
PubMedJournal of theoretical biology2026-06-02

A physiologically based mathematical model describing estradiol and progesterone actions on glucose-insulin dynamics throughout the menstrual cycle.

Mazo Carolina Ramírez CR, Gómez-Echavarría Lina L, Lema-Pérez Laura L, Röblitz Susanna S

Our knowledge about women's health from a systemic physiological perspective, particularly regarding the interactions and multiple feedback loops between the ovulatory-menstrual cycle (OMC) and the rest of the female body, is limited. Mathematical models describing such interactions are scattered, and quantitative studies are often contradictory in the current literature. The impact of the OMC on glucose metabolism in healthy women has not been mathematically modeled so far, and the interactions between those two systems have barely been taken into consideration when addressing altered glucose-insulin dynamics in, e.g., Type 1 Diabetes (T1D), Type 2 (T2D), and gestational diabetes. This constitutes a knowledge gap not only for women with diabetes, but also for comprehending glucose homeostasis in the non-diabetic female population. The mathematical model presented here includes the impact of the OMC on glucose-insulin dynamics described by a minimal model. The phases of the OMC are represented by the dynamics of estradiol (E2) and progesterone (P4), which serve as input to the glucose-insulin model. A physiologically based expression depending on E2 and P4 is introduced to modulate the parameter known as insulin sensitivity, which modulates the glucose (G) state. The dependency on both steroid hormones (E2 and P4) is also introduced in the other two states of the system describing glucose metabolism: 1) in the secretion rate of insulin from β-cells, which affects the insulin (I) state, and 2) in the β-cell mass preservation, impacting the β state. The results are in agreement with physiological descriptions and available data. They demonstrate an essential role of P4 along with E2 effects in glucose homeostasis, i.e., insulin sensitivity, insulin secretion and β-cell maintenance. This work paves the way for future studies in which the hormonal dynamics could be coupled with more detailed metabolic models including, e.g., hepatic glucose metabolism, and it calls for better experimental data to continue deepening our comprehension of these interactions.

PMID 42225224
Read full article →
PubMedDrug design, development and therapy2026-06-02

Roles of Goserelin in Gynecological Disorders.

Huang Xiufeng X, Gu Nihao N, Qian Linhua L, Sun Feng F et al.

Goserelin is a gonadotropin-releasing hormone (GnRH) agonist with a long history of clinical application and well-established efficacy and safety profile. Its mechanism of action centers on sustained GnRH receptor desensitization, leading to pituitary downregulation, ovarian suppression, and reduction of estradiol and progesterone to postmenopausal levels; this forms the basis for its efficacy in hormone-dependent gynecological conditions. Over the past three decades, the use of goserelin has been expanded to an increasing number of indications and clinical scenarios. Approved gynecological indications of goserelin include endometriosis, uterine fibroids, usage as an agent for endometrial thinning, and usage as an agent for ovarian downregulation prior to assisted reproduction. More recent research continues to explore the use of goserelin in gynecological diseases such as adenomyosis and different types of female cancers. Goserelin may also be a useful tool in clinical scenarios where gynecologic management is required as part of multi-disciplinary therapy. This review consolidates the established and emerging roles of goserelin across the broad spectrum of benign and malignant gynecological conditions, underscoring its remarkable clinical versatility and the breadth of evidence that support its continued expansion of utility in contemporary practice.

PMID 42226753
Read full article →
PubMedSteroids2026-06-02

Carnosic acid ameliorates methotrexate-induced male infertility: targeting testicular redox imbalance and nitric oxide/CGMP signaling.

Ajibare Ayodeji Johnson AJ, Adejumo Miracle Oyaname MO, Akanbioluwa Ewaoluwa Faith EF, Adelokiki Ibukunoluwa I et al.

Methotrexate (MTX), a folate antagonist used in the treatment of cancer and autoimmune disorders, unfortunately, induces testicular toxicity and impairs male fertility. Although the tissue-protective properties of Carnosic acid (CAR) are known, its effectiveness in mitigating MTX-induced reproductive toxicity has not been adequately studied. This study explores the protective role of CAR against the toxicity of MTX in rat testes. Forty male Wistar rats were divided into four groups: control, MTX (20 mg/kg i.p., day 7), MTX + low-dose CAR (20 mg/kg p.o., 14 days), and MTX + high-dose CAR (40 mg/kg p.o., 14 days). On day 15, testicular tissue and serum were analyzed for oxidative stress markers (GSH, GPx, MDA), NO/cGMP pathway components (iNOS, NO, cGMP), inflammatory markers (NF- κB, IL-6), steroidogenesis parameters (total cholesterol, 3β-HSD, 17β-HSD), and hormonal levels (GnRH, FSH, LH, testosterone, estradiol). Histopathological examinations were conducted on testicular sections. MTX significantly reduced antioxidant levels, increased lipid peroxidation, disrupted NO/cGMP signaling, elevated inflammation, impaired steroidogenesis, and altered hormone levels, with evidence of histological changes. CAR, especially at higher doses, mitigated these effects, restoring antioxidant status, normalizing NO/cGMP signaling, reducing inflammation, enhancing steroidogenesis, and improving testicular morphology. CAR ameliorates MTX-induced adverse effects in the testes of rats via controlling redox balance, NO/cGMP signaling, inflammation, and steroidogenesis, with the potential of CAR to be used as a treatment to protect male reproductive function during therapy with MTX.

PMID 42225222
Read full article →
PubMedProblemy endokrinologii2026-06-02

[Changes in ovarian function and ovarian reserve after combined treatment for differentiated thyroid cancer].

Korchagina M O MO, Andreeva E N EN, Sheremeta M S MS, Melnichenko G A GA

The paradigm of combined treatment for differentiated thyroid cancer has been in use since the mid-20th century. This approach involves thyroidectomy, followed by radioactive iodine therapy, and after patients may be prescribed suppressive therapy. Combined treatment improves outcomes, particularly in cases of high risk of recurrence. However, it can also lead to a range of secondary complications, including those affecting the reproductive system. Assessment and comparative analysis of ovarian function and ovarian reserve (OR) using anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2) and estrone (E1) in the early follicular phase in women of reproductive age who received combined treatment for DTC, and in healthy women of the same age. In a single-center, comparative cross-sectional study, clinical and morphological, anamnestic and laboratory parameters were analyzed in patients who underwent thyroidectomy and one course of radioiodine therapy for DTC, and in healthy women. The study enrolled 90 women aged 18 to 40 years: 67 women with DTC with a median age of 31 years [26; 36] who underwent combined treatment, and 30 healthy women with a median age of 30 years [28; 35]. The frequency of menstrual cycle disorders over the past year was 33% in women with DPT and 13% in healthy women.When comparing the results of hormonal examination, it was revealed that the levels of FSH, LH, PRL, E1 and E2 did not differ significantly between the groups. The level of AMH was the only parameter that significantly differed in patients with DTC receiving combined treatment and in healthy women - 2.49 ng/ml [1.1; 3.3] and 3.6 ng/ml [2.62; 4.18], respectively (P < 0.004). In 18 (27%) patients with DTC, the level of AMH was < 1.2 ng/ml, in the group of healthy women low level of AMH was found only in one case. Only patient's age at the time of RAIT and age at the time of examination on the background of thyroid stimulating hormone suppression were associated with diminished ovarian reserve, using the Juden index, the cut-off points of 31 years and 33 years were determined, respectively. The level of AMH in patients with DTC who undergo combined treatment is significantly lower compared to healthy women of the same age. Only patient's age at the time of RAIT and age at the time of examination on the background of thyroid stimulating hormone suppression were associated with diminished ovarian reserve.

PMID 42227096
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ethinyl estradiol + norethindrone